Alcon buys Neurotech for $550 million, gaining MacTel therapy ENCELTO

what happened

Alcon (SIX), a global eye care company, has completed its purchase of Neurotech Pharmaceuticals, a privately held biotech firm developing cell-based treatments for chronic eye conditions, according to TradingView. The deal brings ENCELTO into Alcon's retina business. ENCELTO is an encapsulated cell therapy surgically implanted into the eye, and the FDA approved it in March 2025 for adults with MacTel type 2, a rare progressive disease that causes permanent loss of central vision.

Alcon paid $550 million and may owe further contingent payments linked to commercial milestones. The company expects the transaction to modestly boost net sales growth and to be slightly dilutive to core diluted EPS in 2027, turning accretive afterward. ENCELTO is currently sold only in the United States. Goldman Sachs advised Alcon, while J.P. Morgan and Rothschild & Co advised Neurotech. Reuters also reported the deal, though its item contained only the headline.

why it matters

At $550 million, the price is small relative to Alcon's overall size, so the deal is unlikely to change the group's financial picture much in the near term. The main signal for investors is Alcon's push into specialized retinal treatments. The forecast for slight EPS dilution in 2027 and any future milestone payments will be the figures to track when assessing the deal's effect.

market impact

Alcon and eye care sector: mid-sized deal, slight EPS dilution expected in 2027 weighs on near-term earnings

tags

instruments